OmniComm's TrialMaster EDC Solution Selected by Med Device Manufacturer for Phase IV Cardiovascular Device Study
Fort Lauderdale, FL - November 17, 2009
OmniComm Systems, Inc., one of the fastest growing companies in the EDC marketplace, announced today that a leader in the medical device industry has selected OmniComm’s TrialMaster EDC solution for the data capture of a Phase IV cardiovascular study. The 24-months, 7-site study will enroll 100 subjects.
“We look forward to continuing our successful collaboration with this device company,” remarked Stephen Johnson, COO of OmniComm Systems. “Our flagship EDC solution, TrialMaster, has already proven to be an efficient and reliable data capture system for 12 of this customer’s studies during the past 5 years."
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Beyond the Molecule: How Human-Centered Design Unlocks AI's Promise in Pharma
June 23rd 2025How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.
